EGFR and cancer: Erlotinib is an effective human epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), which was approved for the treatment of advanced pancreatic cancer in combination with gemcitabine as well as for other malignant tumors such as lung cancer [6, 7].